Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S

Molecular oncology of lung cancer.

Gen Thorac Cardiovasc Surg 59:527-37 (2011)
DOI:10.1007/s11748-010-0743-3

Lee DH

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.

Pharmacol Ther 174:1-21 (2017)
DOI:10.1016/j.pharmthera.2017.02.001

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

N Engl J Med 350:2129-39 (2004)
DOI:10.1056/NEJMoa040938

Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

PLoS Med 2:e313 (2005)
DOI:10.1371/journal.pmed.0020313

Yasuda H, Kobayashi S, Costa DB

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

Lancet Oncol 13:e23-31 (2012)
DOI:10.1016/S1470-2045(11)70129-2

Sullivan I, Planchard D

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.

Front Med (Lausanne) 3:76 (2016)
DOI:10.3389/fmed.2016.00076